Advance Cancer Immunotherapy

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology firm specializing in targeted immunotherapies, has successfully priced its public offering of 5,000,000 shares of common...